Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated. Other first-line treatments have failed, but research remains active and trials are ongoing with promising new anti-cancer agents. These new effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials and a recent trial have failed to demonstrate the added value of classical external radiotherapy in this setting. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future. Â© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: firstname.lastname@example.org.
|Number of pages||11|
|Journal||Annals of oncology : official journal of the European Society for Medical Oncology|
|Publication status||Published - 2017|
Taieb, J., Pointet, AL., Van Laethem, JL., Laquente, B., Pernot, S., Lordick, F., & Reni, M. (2017). What treatment in 2017 for inoperable pancreatic cancers? Annals of oncology : official journal of the European Society for Medical Oncology, 28(7), 1473-1483. https://doi.org/10.1093/annonc/mdx174